Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,049 across all filing types
Latest filing 2021-08-03 Regulatory Filings
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings
2021-08-03 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated August 2, 2021, announcing Glenmark Pharmaceuticals' agreement with Canadian biotech SaNOtize to commercialize a Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets. It contains no financial data, no regulatory filings, no voting results, no management or board changes, no earnings or annual report content. It is a corporate announcement about a strategic partnership and product commercialization. The document is about a business update and partnership announcement rather than a financial or regulatory report. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general corporate announcement that does not fit other specific categories.
2021-08-02 English
Updates
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the filing and approval of a Red Herring Prospectus (RHP) for the initial public offering (IPO) of a wholly owned subsidiary. It provides details about the IPO timeline, issue size, and listing date. The document is an announcement about a capital raising event and related regulatory filing, specifically concerning the IPO process. It is not a full financial report, earnings release, or management discussion. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short and it is an announcement rather than a detailed report, but it is not merely a report publication announcement or regulatory filing fallback. Hence, Capital/Financing Update is the most appropriate classification.
2021-07-20 English
Related Party Transactions
Regulatory Filings
2021-06-25 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Glenmark Pharmaceuticals has received tentative approval from the U.S. FDA for a generic drug (Nintedanib Capsules). It is addressed to stock exchanges and includes a media release. There are no financial statements, detailed financial data, or regulatory filings such as annual or quarterly reports. The document is short (3848 characters) and primarily serves as a corporate announcement about a product approval. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is an announcement related to company operations and product approvals, which is best classified as a Regulatory Filing (RNS) since it does not fit other specific categories and is a general regulatory announcement to stock exchanges.
2021-06-25 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated June 23, 2021, from Glenmark Pharmaceuticals announcing the receipt of ANDA (Abbreviated New Drug Application) approval from the U.S. FDA for a specific pharmaceutical product. It is addressed to stock exchanges and includes a request to take the announcement on record. The content is a media release about a regulatory approval event, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis. The document is short (4675 characters) and serves as an announcement of a corporate event related to product approval. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-06-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.